THURSDAY | AUGUST 20, 2020
|
|
|
|
Pain Physician
COVID-19 Special Issue Now Online
|
|
Pain Physician, the official journal of ASIPP, has launched a special issue covering COVID-19 issues. The publications range from understanding the pathophysiological mechanisms, epidemiology, implications on interventional pain practices, safety and effectiveness of various modalities of drug therapy, telemedicine, along with the effect on interventional pain management practices, and, finally, the technological impact of COVID-19 on the future of education and health care delivery and multiple guidelines. |
|
Guidelines
Shalini Shah, MD, Sudhir Diwan, MD, Amol Soin, MD, Kartic Rajput, MD, PhD, Amit Mahajan, MBBS, Laxmaiah Manchikanti, MD, Alan D. Kaye, MD, PhD, Joshua A. Hirsch, MD, and Christopher Gharibo, MD
Christopher Gharibo, MD, Amit Sharma, MD, Amol Soin, MD, Shalini Shah, MD, Sudhir Diwan, MD, Ricardo Buenaventura, MD, Devi E. Nampiaparampil, MD, Steve M. Aydin, DO, Sanjay Bakshi, MD, Salahadin Abdi, MD, PhD, Sachin “Sunny” Jha, MD, MS, Harold J. Cordner, MD, Alan D. Kaye, MD, PhD, Alaa Abd-Elsayed, MD, Kenneth D. Candido, MD, Nebojsa Nick Knezevic, MD, PhD, Sairam Atluri, MD, Bradley W. Wargo, DO, Mahendra R. Sanapati, MD, Sukdeb Datta, MD, Joshua A. Hirsch, MD, and Laxmaiah Manchikanti, MD
Systematic Review
Nebojsa Nick Knezevic, MD, PhD, Laxmaiah Manchikanti, MD, Ivan Urits, MD, Vwaire Orhurhu, MD, MPH, Brahma Prasad Vangala, MBBS, Rachana Vanaparthy, MBBS, Mahendra R. Sanapati, MD, Shalini Shah, MD, Amol Soin, MD, Amit Mahajan, MBBS, Sairam Atluri, MD, Alan D. Kaye, MD, PhD, and Joshua A. Hirsch, MD
Survey
Sachin “Sunny” Jha, MD, MS, Shalini Shah, MD, Michael David Calderon, MS, Amol Soin, MD, and Laxmaiah Manchikanti, MD
AND SO MUCH MORE...
|
|
Pre-Registrants Receive Live Meeting Credentials Plus Access to Videos for 30-Days After Meeting Ends
Great Reasons to Attend:
- Save time and money: More time in the office with patients and no fear of COVID-19 exposure.
-
Attend the meeting from wherever you want with just about any device.
-
Earn up to 19.75 CMEs.
- For pre-registrants who want to revisit the meeting after the 30-day bonus access ends, we will make the meeting videos and exhibit hall available until next summer for a nominal fee.
- Catch up with your peers from across the country through the many networking tools.
- World-renowned speakers on relevant subjects to IPM, COVID-19 interfacing with IPM, and many other subjects including opioids and regenerative medicine.
- Virtual exhibit hall like nothing you have seen before.
If you have already registered for the Annual Meeting, your registration fee has been transferred to the Virtual Annual Meeting. You will receive your virtual meeting login credentials and CME information late next week.
|
|
Order Now - Recorded Virtual Review Courses
The following courses are offered:
- Documentation, Coding, Compliance, and Practice Management Review Course
- Controlled Substance Management Review Course
- *Pain Medicine and Interventional Pain Management Comprehensive Review Course
*not available until the end of the live course July 26, 2020
|
|
ABIPP Recognizes Your Knowledge and Expertise
The American Board of Interventional Pain Physicians (ABIPP) has developed certification programs that recognize accepted levels of knowledge and expertise in the interventional pain management profession, with the goal of improved patient care. Hundreds of qualified physicians have made the commitment to become ABIPP certified.
ABIPP now offers the only competency
certification program for regenerative medicine.
For complete information about the examination requirements and to obtain an application packet, visit www.abipp.org or call 270-554-9412 x4217 or by email at summer@asipp.org.
|
|
TESTS OFFERED
ABIPP Part I - Theoretical written exam - TBD
ABIPP Part II - Oral and Hands-on practical exam - TBD
ABIPP Competency Exam - includes written, oral, and hands-on practical examinations TBD
Combined CSM/CCPM Exam for ABIPP Path – TBD
Competency Exam in Controlled Substance Management – TBD
Competency Exam in Coding, Compliance, and Practice Management - TBD
Regenerative Medicine Competency Exam - includes written, oral, and hands-on practical examinations – TBD
|
|
|
HHS reopens applications for COVID-19 provider assistance
- A new chance to apply for CARES Act grants was offered to providers that previously rejected the funds, among other prospective applicants.
- Some providers returned the initial CARES Act grants.
- New legislation would prevent not-for-profit providers from owing taxes on the grants.
Providers that rejected or missed applying for federal grants to mitigate revenue shortfalls from the COVID-19 pandemic will have another chance to apply.
The U.S. Department of Health and Human Services (HHS) on Aug. 10 announced it has reopened the application process, which had closed June 3, for providers to garner Provider Relief Fund (PRF) payments.
The assistance from the $50 billion general-distribution fund created by the Coronavirus Aid, Relief and Economic Security (CARES) Act is open to:
- Providers that rejected and returned the initial funding but are now interested in obtaining funds
- Providers that previously missed applying
- Medicaid and Children’s Health Insurance Program (CHIP) providers
- Dental providers with low Medicare revenues
- Providers with a change in ownership that now makes them eligible
- Providers that did not have Medicare fee-for-service revenue in 2019
Applications for the latest grants, which will provide 2% of a recipient’s total patient care revenue, are due Aug. 28.
|
|
CDC Details COVID-19's Massive Mental Health Impact
— Young adults, people of color, essential workers, and adult caregivers particularly affected
Nearly 11% of American adults seriously considered suicide this June, according to CDC data.
Among 5,470 people surveyed in the last week of June, 30.9% reported symptoms of an anxiety or a depressive disorder, 25.3% reported a traumatic or stressor-related disorder (TSRD), and 13.3% said they were using substances to cope with the pandemic's stressors, said Rashon Lane, MA, of the CDC's COVID-19 Response Team.
And 10.7% reported seriously considering suicide in the prior month, more than double the rate reported in a 2018 CDC survey, the researchers wrote in the agency's Morbidity and Mortality Weekly Report.
|
|
Evidence grows that children may play a larger role in transmission than previously believed
As schools reopen in parts of the United States, a paper published Thursday found that some children have significantly higher levels of virus in their airways than the most severely ill adults — suggesting their role in community spread may be larger than previously believed.
The study in The Journal of Pediatrics comes on the heels of two others that offer insights about children and covid-19 transmission. On July 30, researchers reported in JAMA that children younger than 5 with mild or moderate illness have much higher levels of virus in the nose compared to older children and adults. Shortly before that, investigators in South Korea found in a household study that older children passed on the virus as readily as adults, while younger children did not.
All three studies involved only a small number of youth — and they contradicted each other in some details — so researchers said they could not make any definitive conclusions based on any one of them alone. But taken together, they paint a worrisome new picture of children’s role in the pandemic.
|
|
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2020–21 Influenza Season
Summary
This report updates the 2019–20 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2019;68[No. RR-3]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available. Most influenza vaccines available for the 2020–21 season will be quadrivalent, with the exception of MF59-adjuvanted IIV, which is expected to be available in both quadrivalent and trivalent formulations.
Updates to the recommendations described in this report reflect discussions during public meetings of ACIP held on October 23, 2019; February 26, 2020; and June 24, 2020. Primary updates to this report include the following two items. First, the composition of 2020–21 U.S. influenza vaccines includes updates to the influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B/Victoria lineage components. Second, recent licensures of two new influenza vaccines, Fluzone High-Dose Quadrivalent and Fluad Quadrivalent, are discussed. Both new vaccines are licensed for persons aged ≥65 years. Additional changes include updated discussion of contraindications and precautions to influenza vaccination and the accompanying Table, updated discussion concerning use of LAIV4 in the setting of influenza antiviral medication use, and updated recommendations concerning vaccination of persons with egg allergy who receive either cell culture–based IIV4 (ccIIV4) or RIV4.
The 2020–21 influenza season will coincide with the continued or recurrent circulation of SARS-CoV-2 (the novel coronavirus associated with coronavirus disease 2019 [COVID-19]). Influenza vaccination of persons aged ≥6 months to reduce prevalence of illness caused by influenza will reduce symptoms that might be confused with those of COVID-19. Prevention of and reduction in the severity of influenza illness and reduction of outpatient illnesses, hospitalizations, and intensive care unit admissions through influenza vaccination also could alleviate stress on the U.S. health care system. Guidance for vaccine planning during the pandemic is available at https://www.cdc.gov/vaccines/pandemic-guidance/index.html.
|
|
New Drug Application for Remdesivir Submitted
The New Drug Application (NDA) for remdesivir (Veklury®; Gilead Sciences) has been submitted to the Food and Drug Administration (FDA) for the treatment of patients with coronavirus disease 2019 (COVID-19).
Remdesivir is an investigational nucleotide analogue with broad-spectrum antiviral activity. It is currently available in the US under an Emergency Use Authorization (EUA) for patients with suspected or laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19. The rolling NDA submission was initiated on April 8, 2020.
The application is supported by data from 2 randomized, open-label, multicenter phase 3 clinical studies (NCT04292730 and NCT04292899) conducted by Gilead and a randomized, placebo-controlled, phase 3 study (NCT04280705) conducted by the National Institute of Allergy and Infectious Diseases (NIAID). The studies evaluated the efficacy and safety of remdesivir in hospitalized patients with COVID-19. Patients were administered 200mg of remdesivir intravenously on the first day, followed by 100mg daily thereafter for 5 or 10 days.
|
|
ASIPP® Partners with Fedora Billing And Revenue Cycle Management Company
|
|
ASIPP is now able to offer unique benefits for revenue cycle management with billing, etc.
Fedora is a company known to many of our board members and others. ASIPP® has reached an agreement with Fedora to provide exclusive discounts on billing or revenue cycle management that will decrease practice costs and promote growth, or at least stop deterioration. It is not just a billing company; they streamline the billing and receivable process and constantly update payor regulations keeping your practice up to on date on a daily basis.
Some of the ASIPP® Billing Program highlights are below:
Up to 50% savings for ASIPP® members for their billing or revenue cycle management for their offices and surgery centers:
- Expertise in interventional pain management billing for all types of services
- 99% Clearing House Rate
- 95% First-Time Claim Passage
- 23.4 Average Days in A/R
- Eligibility and Benefits Verification
- Pre-Certification/Prior Authorization
- Denials and A/R Management
|
|
Join The Group Purchasing
Organization Today
|
|
ASIPP® has formed a partnership with Henry Schein and PedsPal, a national GPO that has a successful history of negotiating better prices on medical supplies and creating value added services for the independent physician. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today. While the cost of contrast media has skyrocketed due to the single dose vial issue, because we have partnered with Henry Schein, this could enable you to purchase Omnipaque 240mg/50mL for slightly above $4.50.
Click on “view our discounted supplier prices” (Username: ASIPPmember and Password: Save) or click on the words "join for free now" and begin saving today!
|
|
Essentials of Regenerative Medicine in Interventional
Pain Management
|
|
|
|
Essentials of Regenerative Medicine in Interventional Pain Management is a book to bring concise, collective, and comprehensive information to interventional pain physicians practicing regenerative medicine in managing chronic pain. Regenerative medicine is an integral part of interventional pain management within the definitions of interventional pain management and interventional techniques.
Each chapter contains an introduction of the subject, historical context,pathophysiology, applicability of regenerative medicine with its evidence base, indications, anatomy, technical aspects, complications, and precautions for each topic when available and applicable. This comprehensive book consists of 35 chapters, more than 350 figures, and 50 tables.
|
|
| ORDER | Essentials of Regenerative Medicine in IPM
|
|
Control Your Waiting Room TV
Customized waiting room TV exclusively for ASIPP® members. Create your own ad-free television broadcasts using our videos, custom informational slides and your own YouTube videos. Even add local weather reports, news and live messages.
|
|
|
In addition, PainExam has now collaborated with ASIPP and offer 2 new programs:
|
|
|
|
|
GSIPP 16th Annual Pain Summit |
|
The Ritz-Carlton Reynolds Plantation
Lake Oconee
|
|
|
|
|
|
|
2020 12th Annual Scientific
Meeting
|
|
|
|
|
|
|
|
|
|
